Suono Bio, Inc. Announces Strategic Investment by FUJIFILM Corporation to Advance Pipeline of Novel Treatments for Inflammatory-Mediated Diseases

September 5th, 2018 – CAMBRIDGE, Mass., Suono Bio, Inc. announced today a strategic investment by FUJIFILM Corporation to advance Suono Bio's second-generation platform technology for the ultra-rapid, formulation-independent administration of therapeutics including biologics and gene therapies.

Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases. The company has demonstrated pre-clinical activity in a range of diseases using a diverse set of therapeutics, including genetic material, at clinically-relevant doses. The company was founded by Professor Langer, Dr. Giovanni Traverso, a gastroenterologist and biomedical engineer at Brigham and Women's Hospital, Harvard Medical School, Ms. Amy Schulman, Partner at Polaris Partners and Executive Chair of Suono Bio, and Dr. Carl Schoellhammer, who also served as founding CEO. In addition to Polaris Partners, Suono Bio is backed by MIT's The Engine, a unique venture capital firm founded by MIT to invest in Tough Tech companies, and MedTech Venture Partners, which funds and supports medical technology entrepreneurs.

“I am thrilled that we have the opportunity to forge a long and fruitful relationship with Fujifilm to advance the development of our core technology. Their investment is a critical validation of our platform,” said Dr. Schoellhammer. “FUJIFILM has deep technical expertise and offers the chance to accelerate our development by working closely with their scientists and engineers in the future,” added Professor Langer.

ABOUT SUONO BIO
Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com.

ABOUT FUJIFILM
FUJIFILM Holdings Corporation, Tokyo, Japan, brings innovative solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These
products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23.0 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.